Treatment for Severe Concentric Left Ventricular Hypertrophy

Pharmacological Management Based on Etiology

The American College of Cardiology recommends non-vasodilating beta-blockers titrated to maximum tolerated dose as first-line therapy for obstructive Hypertrophic Cardiomyopathy (HCM) with LVH 1, 4
The American College of Cardiology suggests verapamil or diltiazem can be used in patients with obstructive HCM who are intolerant to beta-blockers 4, 1
For patients with obstructive HCM who have persistent symptoms despite beta-blockers or calcium channel blockers, the American College of Cardiology recommends adding a myosin inhibitor (adults only), disopyramide, or septal reduction therapy 5
The American Heart Association implies that ACE inhibitors are equally effective as ARBs in reducing LVH and can be considered as alternative first-line agents when ARBs are not tolerated 1, 2

The American College of Cardiology recommends a target blood pressure of <130/80 mmHg for most patients with LVH 3
Blood pressure control should remain the primary goal of therapy, as adequate BP reduction is essential for LVH regression, according to the American Heart Association 1

Regular aerobic exercise, body weight control, and dietary modifications are recommended by the American Heart Association 3
Sodium restriction is advised as part of dietary modifications by the American Heart Association 3
Weight loss of 5 pounds or greater has been associated with reductions in cardiovascular risk of about 40%, according to the American Heart Association 6

Non-dihydropyridine calcium channel blockers, alpha-blockers, potent direct-acting vasodilators, and nonsteroidal anti-inflammatory agents should be avoided in patients with LVH due to hypertension, according to the American College of Cardiology 3
In pregnant women, mavacamten (a myosin inhibitor) is contraindicated due to potential teratogenic effects, as stated by the American College of Cardiology 5

Treatment-induced reduction in left ventricular mass is significantly and independently associated with reduction in major cardiovascular events, stroke, and cardiovascular and all-cause mortality, according to the American College of Cardiology 1

For patients who develop systolic dysfunction with LVEF <50%, the American College of Cardiology recommends guideline-directed medical therapy for heart failure with reduced ejection fraction 4
If a patient with HCM develops persistent systolic dysfunction (LVEF <50%), the American College of Cardiology suggests cardiac myosin inhibitors should be discontinued 5